65 /100
HIGH RISK
Score updated Jul 14, 2026

CTXR — Citius Pharmaceuticals, Inc. Dilution Risk Tracker

Track CTXR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CTXR — Get alerts when the score changes →

As of July 14, 2026, Citius Pharmaceuticals, Inc. (CTXR) has a DilutionWatch DilutionScore of 65/100, rated HIGH dilution risk. Citius Pharmaceuticals, Inc. has a market capitalization of $17.98M, 27.45M shares outstanding, 15 institutional holders tracked. Key dilution vectors include ATM program capacity of $250.00M, 5.14M outstanding warrants, approximately 2 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
50
💰 Cash Runway
95
📊 Float Risk
20
⚠️ Warrant Exposure
50
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
62%
💰 Capital Raise 73%
• Critical: only 1.9 months cash remaining
• Active ATM program with $250M remaining capacity
🔄 Reverse Split 70%
• 50-day avg $0.74 below $1 exchange minimum
• Only 2 months cash — financial pressure
📜 Warrant Exercise 25%
• Significant warrants: 19% of shares outstanding
🔔 Track CTXR — Get forecast alerts →

💹 Market Data

Market Cap$17.98M
Shares Outstanding27.45M
Float26.96M
Cash$4.59M
Debt$808.2K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 113.4% shares (2026Q1 vs prior)
15 institutional holders · 14.78M shares
#1 ARMISTICE CAPITAL, LLC 9.19M shares
#2 BANK OF AMERICA CORP /DE/ 3.84M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 1.07M shares
+ 12 more holders Sign up free to view →

📉 Short Interest

Short Interest4.76M
Days to Cover23.4
% of Float17.7%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Sep 10, 2025
xbrl XBRL CONVERTIBLE Sep 30, 2016
8-K 8K EVENT Apr 24, 2026
424B5 ATM Apr 24, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for CTXR Shareholders

Citius Pharmaceuticals, Inc. (CTXR) has a DilutionScore of 65/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

CTXR has an active ATM (at-the-market) program with $250.0M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event. DilutionWatch tracks 5.1M outstanding warrants for CTXR. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window.

DilutionWatch tracks over 25 SEC filing types for CTXR in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for CTXR alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

How ATM Offerings Work → Warrants Explained →
Track CTXR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CTXR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for CTXR
📊 CTXR FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 CTXR Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.